IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

What's the purpose of the trial?

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
128
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 13 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cyclophosphamide
  • Daratumumab
  • Fludarabine
  • IDP-023
  • Interleukin-2
  • Mesna
  • Rituximab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Phase 1: IDP-023 (Single Dose)

Accepting patients

Phase 1: IDP-023 (Multiple Doses)

Accepting patients

Phase 1: IDP-023 + IL-2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.